Home > Boards > US OTC > Biotechs >

Antibe Therapeutics Inc. (ATBPD)

ATBPD RSS Feed
Add ATBPD Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/27/2020 4:33:32 PM - Followers: 17 - Board type: Free - Posts Today: 0

logo
http://www.antibethera.com/wordpress/pdf/presentations/Antibe%20Investor%20Presentation%20-%20July%202019.pdf


http://www.antibethera.com/pipeline/ 









Gastric ulcer incidence of ATB-346 (>=3mm diameter) versus naproxen during two-week treatment period # of Subjects that Developed Ulcers 0 15 30 45 60 ATB-346 Naproxen 11 • A successful Phase 2B double blind GI safety study for ATB-346 was completed in March 2018 in 244 healthy volunteers • Validation of GI safety superiority: ATB-346 exhibited an ulceration rate of 2.5% versus 42.1% for naproxen over the two-week treatment period (p<0.0001) • ATB-346 was safe and well-tolerated Strong Phase 2B GI Safety Data 42.1% 2.5% (n = 118) (n = 126)

 

H2S Platform

HOME / H2S PLATFORM

Antibe Therapeutics is pursuing a major advance in the safe and non-addictive treatment of pain and inflammation. Our drugs are designed to prevent the widespread and serious gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs (“NSAIDs”), today’s most widely used medicines for the relief of pain. The NSAID class of drugs includes prescription and over-the-counter (“OTC”) brands such as naproxen (Aleve), celecoxib (Celebrex), ibuprofen (Advil), and Aspirin.

Global NSAID sales exceed $11 billion annually, a significant market opportunity that could potentially be disrupted by Antibe’s H2S technology.

Now in Phase 2 human clinical trials, Antibe’s lead drug, ATB-346, targets mild-to-moderate pain and inflammation arising from a wide range of medical conditions. In March 2018, ATB-346 showed unequivocal superiority to naproxen in GI safety (2.5% versus 42.1% ulceration rate) in a Phase 2B double-blind clinical trial (see press release). This human proof-of-concept data replicated the results of our pre-clinical studies, and suggests Antibe has potentially surmounted the main barrier to the non-addictive control of pain and inflammation. If ATB-346 obtains regulatory approval, physicians and consumers will gain a radically safer alternative to today’s NSAIDs and to the multi-dimensional dangers of corticosteroids (used for inflammation) and opiates (used for pain).

Antibe has two other promising drug candidates in its pipeline: ATB-352, a potent pain-killer targeting the urgent global need for a safer, non-addictive analgesic for treating severe pain; and ATB-340, GI-safe derivative of aspirin for chronic prevention of cardiovascular disease and cancer chemoprevention.

Rooted in more than ten years of academic and proprietary research, Antibe’s patent-protected drug development technology enables the linking of an NSAID molecule to a hydrogen sulfide-releasing molecule. Notably, hydrogen sulfide (“H2S”) is endogenously produced and utilized throughout the body, serving as an anti-inflammatory agent and signaling molecule. Combined with an expanding scope of indications for NSAID use, the unique properties of hydrogen sulfide promise substantially improved medicines for pain and inflammation across the spectrum of human illness.

ATB-346
Novel anti-inflammatory drug that releases hydrogen sulfide (“H2S”) • Negligible GI damage: greatly superior to existing NSAIDs • No significant effect on blood pressure, unlike existing NSAIDs • Global IP with market protection to ~2030 - Patents granted in major markets (including US, Europe, Japan, China & Canada) 
ATBPD
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#307   ATBPF one for 10 reverse split. **PPS closed Renee 11/27/20 04:33:32 PM
#306   Not great seemingly dubt 11/13/20 10:36:33 PM
#305   See how the Canadian up listing will treat dubt 11/12/20 09:18:37 AM
#304   386,782,798 added another million plus to the o/s DirtyPenny 11/03/20 12:17:13 PM
#303   Interesting biotech that has almost no volume, compared Ecomike 10/19/20 07:32:11 PM
#302   more added, outstanding now 385,516,301 DirtyPenny 08/21/20 01:22:12 PM
#301   continues to be shit on janeyH 06/26/20 05:36:07 PM
#300   added 19 million shares since 3/30, is this DirtyPenny 06/26/20 05:31:33 PM
#299   continues to be shit on janeyH 06/10/20 12:26:40 PM
#298   Halt! treedoc 06/09/20 04:09:35 PM
#297   Heard the cc and Q&A They were all very Amatuer17 06/05/20 12:32:12 PM
#296   Yeah, not sure if people were just expecting dubt 06/04/20 11:17:09 AM
#295   wow, but continued doo-doo-ing in the stock - janeyH 06/04/20 11:12:44 AM
#294   Everything positive from the CC. lots of details, dubt 06/04/20 11:11:25 AM
#293   great - pls let us know what you think janeyH 06/04/20 09:55:05 AM
#292   I’m on it dubt 06/04/20 09:54:23 AM
#291   can’t make it - can anyone else? janeyH 06/04/20 09:45:43 AM
#290   Conference call June 4 dubt 06/02/20 06:51:48 PM
#289   Especially given the volume here two days of janeyH 06/02/20 11:46:23 AM
#288   Agree - I cannot see any update from Amatuer17 06/02/20 11:23:49 AM
#287   i am surprised by the degree of the janeyH 06/02/20 09:56:45 AM
#286   I sold 30k at .45 and got out, waltd 06/01/20 02:43:27 PM
#285   happens often, investors buy the rumor/speculation, then sell DirtyPenny 06/01/20 11:02:52 AM
#284   The market is failing to price these results Mogles 06/01/20 11:01:07 AM
#283   Very good news Amatuer17. treedoc 06/01/20 07:56:09 AM
#282   Results out - they look very good as Amatuer17 06/01/20 07:38:18 AM
#281   Woot! Ty! NotTheFace1337 05/29/20 10:06:52 PM
#280   https://www.bnnbloomberg.ca/video/robert-mcwhirter-discusses-antibe-therapeutics djmurdock 05/29/20 09:10:48 PM
#279   So what I miss lol? NotTheFace1337 05/29/20 07:31:12 PM
#278   https://www.facebook.com/watch/?v=365342554408162 djmurdock 05/11/20 08:58:10 PM
#277   I expected a delay, just not that much. djmurdock 05/06/20 09:43:51 PM
#276   Great hire in Dr Stauffer as Chief Medical Mogles 05/06/20 09:46:28 AM
#275   Another 6 weeks, apparently.....:-( Mindoro99 05/04/20 08:31:08 AM
#274   6 more weeks - well at least they Amatuer17 05/04/20 07:35:36 AM
#273   Tick tock Tick tock....any day now. djmurdock 04/30/20 08:21:41 PM
#272   This week or next at the latest according dubt 04/26/20 06:02:32 PM
#271   Will we get the results this week? Amatuer17 04/26/20 06:00:35 PM
#270   Yeah in correspondence with the company. They dubt 04/21/20 09:14:31 PM
#269   Still waiting for the results - overdue but Amatuer17 04/21/20 09:24:47 AM
#268   https://marsdd.com/magazine/10-canadian-health-innovators-covid-19-you-need-to-k djmurdock 04/20/20 08:50:31 PM
#267   No, it was just an interview. Getting the dubt 04/19/20 08:33:20 PM
#266   Any special update? Amatuer17 04/18/20 08:26:11 PM
#265   Thanks! Mindoro99 04/18/20 12:03:32 PM
#264   Tune into Bloomberg tonight 5 eastern to see dubt 04/18/20 09:43:58 AM
#263   Results out possibly next Monday. Smashing through resistance djmurdock 04/13/20 01:19:37 PM
#262   People are expecting the results to come this Amatuer17 04/13/20 11:53:07 AM
#261   Absolutely, can't believe this sunk to .29 or Mindoro99 04/13/20 10:52:53 AM
#260   Nice move on excellent volume so far today! GLTA Murocman murocman 04/13/20 10:39:58 AM
#259   From the talk (without much investment detail) he dubt 04/10/20 08:38:13 AM
#258   Very long talk - too much information but Amatuer17 04/10/20 07:21:38 AM
PostSubject
Consent Preferences